104.33 USD
▼-1.36-0.25%
盘后 104.59 0.00%
2026-08-03
市值
$6.36B
市盈率
—
EPS
-15.17
股息率
—
52 周区间
50.25 – 130.00
成交量
591.58K
Beta
0.48
目标价
146.50
52W 低 50.2552W 高 130.00
价格走势
公司简介
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...